Capmatinib specifically targets the MET gene, which can be abnormally activated in some cancers. This abnormal activation can occur due to mutations or amplifications in the MET gene. By inhibiting the MET receptor, capmatinib can hinder the proliferation of cancer cells and induce apoptosis, or programmed cell death. This makes it particularly effective in cancers where MET dysregulation is a key driver of disease progression.
